Parkinson’s disease (PD) is characterized by well-defined motor symptoms, the most striking of which is bradykinesia. Bradykinesia is typically caused by a reduction in dopaminergic transmission and is reliably reversed by clinically proven drugs.

However, given the limited success of dopamine replacement therapies in PD patients, non-dopaminergic therapeutics to treat PD symptoms and underlying disease are being developed. These new approaches require more sophisticated tools to investigate the impact of therapy in rodent models.

This webinar discusses the evolution of tools to analyze motor deficits in animal models, how that evolution is being informed by clinical strategies and how Charles River is working to support the discovery of future PD treatments.


  • Robert Hodgson, PhD, Director, Science R&D, Charles River

Want to learn more about our work with Parkinson's disease?

A recent article from Bioscience Technology discusses our renewed partnership with the Michael J. Fox Foundation to study Parkinson's disease.

Read More »